Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
To study how the body absorbs, distributes, metabolises and eliminates Keppra XR in both
children (12 to 16 years old) and adults (18 to 55 years old) with epilepsy.